3/10
08:30 am
bdrx
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP
High
Report
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP
3/6
09:38 am
bdrx
Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP [Yahoo! Finance]
Medium
Report
Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP [Yahoo! Finance]
3/6
08:30 am
bdrx
Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP
Low
Report
Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP
2/24
09:04 am
bdrx
Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use [Yahoo! Finance]
Low
Report
Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use [Yahoo! Finance]
2/24
08:30 am
bdrx
Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use
Medium
Report
Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use
2/13
09:40 am
bdrx
Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 [Yahoo! Finance]
Medium
Report
Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 [Yahoo! Finance]
2/13
08:30 am
bdrx
Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025
Medium
Report
Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025
2/10
08:30 am
bdrx
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
Medium
Report
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
1/22
08:30 am
bdrx
Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer
Medium
Report
Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer